| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000026274 |
| Receipt No. | R000030173 |
| Scientific Title | An evaluation test for intestinal environment change in consumption of the spore-forming lactic acid bacteria |
| Date of disclosure of the study information | 2017/02/24 |
| Last modified on | 2020/10/05 (Ver. 3) |
| Basic information | ||
| Public title | An evaluation test for intestinal environment change in consumption of the spore-forming lactic acid bacteria | |
| Acronym | An evaluation test for intestinal environment change in consumption of the spore-forming lactic acid bacteria | |
| Scientific Title | An evaluation test for intestinal environment change in consumption of the spore-forming lactic acid bacteria | |
| Scientific Title:Acronym | An evaluation test for intestinal environment change in consumption of the spore-forming lactic acid bacteria | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To verify the influence for intestinal environment by consumption of the spore-forming lactic acid bacteria. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | *Improvement of bowel movement
*Evaluation of intestinal microbiota by 16S metagenomic analysis * Evaluation of intestinal metabolites by metabolome analysis |
| Key secondary outcomes | * Skin tests
* The incidence of adverse events * The incidence of side effects |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Take 1 tablet of test food at a time, 3 times a day after every meal, for 28 days -- Washout 4 weeks --Take 1 tablet of placebo at a time, 3 times a day after every meal, for 28 days | |
| Interventions/Control_2 | Take 1 tablet of placebo at a time, 3 times a day after every meal, for 28 days -- Washout 4 weeks -- Take 1 tablet of test food at a time, 3 times a day after every meal, for 28 days | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Healthy males and females aged 30 to 49 years old. (Target half a ratio of men and women)
2) Subjects who defecate 3 to 5 times in a week. 3) Subjects who do not routinely use medicines or the gastrointestinal related health foods during the examination period. 4) Subjects who show understanding of the study procedures and agreement with participating the study by written informed consent prior to the study. |
|||
| Key exclusion criteria | 1)Subject who concern difficult to carry out skin test, due to having birthmarks, scratches and a lot of acne on the skin.
2) Subject who have undergone abdominal surgery within 6 months. 3) Subject who took antibiotics within 6 months. 4) Subject who have allergy to the test food. 5) Smoker 6) Subjects whose consort or partner also participates to same clinical test. 7) Subjects who plan big change of lifestyle during test period. 8) Subjects with tendency of chronic diarrhea. 9) Subjects who considered unfitness for the test because of having previous and/or current medical history of serious disease of liver, kidney and heart. 10) Subjects who suspected chronic or serious infectious disease. 11) Females who are pregnant or are lactating. And/or females who are the possibility of pregnancy. 12) Subjects who have participated in other clinical studies within 3 months. 13) Subjects who routinely use food for specific health use, functional foods and/or health foods. 14) Other subjects who have been determined ineligible by principal investigator or sub-investigator. |
|||
| Target sample size | 24 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Planning & Sales Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| Homepage URL | |||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Sponsor | |
| Institute | CPCC Company Limited |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Metagen, Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | DAIICHI SANKYO HEALTHCARE CO., LTD. |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| Address | 2F Chushin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan |
| Tel | 03-5297-5548 |
| IRB@cpcc.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030173 |